Published in Stat Med on October 16, 2012
Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis. Bioinformatics (2014) 0.89
On representing the prognostic value of continuous gene expression biomarkers with the restricted mean survival curve. Oncotarget (2015) 0.78
Comparing gene expression data from formalin-fixed, paraffin embedded tissues and qPCR with that from snap-frozen tissue and microarrays for modeling outcomes of patients with ovarian carcinoma. BMC Clin Pathol (2015) 0.78
Pathway-Structured Predictive Model for Cancer Survival Prediction: A Two-Stage Approach. Genetics (2016) 0.75
Identification of prognostic genes and gene sets for early-stage non-small cell lung cancer using bi-level selection methods. Sci Rep (2017) 0.75
IPI59: An Actionable Biomarker to Improve Treatment Response in Serous Ovarian Carcinoma Patients. Stat Biosci (2016) 0.75
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res (2009) 28.60
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
The lasso method for variable selection in the Cox model. Stat Med (1997) 18.10
Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics (2000) 10.63
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol (2008) 3.89
A group bridge approach for variable selection. Biometrika (2009) 2.61
Has the revolution arrived? Nature (2010) 2.47
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res (2005) 2.37
Nonparametric pathway-based regression models for analysis of genomic data. Biostatistics (2006) 2.28
Averaged gene expressions for regression. Biostatistics (2006) 2.03
Supervised group Lasso with applications to microarray data analysis. BMC Bioinformatics (2007) 1.99
Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med (2009) 1.88
Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS One (2010) 1.58
A prognostic gene expression index in ovarian cancer - validation across different independent data sets. J Pathol (2009) 1.55
Univariate shrinkage in the cox model for high dimensional data. Stat Appl Genet Mol Biol (2009) 1.50
Individualization of therapy using Mammaprint: from development to the MINDACT Trial. Cancer Genomics Proteomics (2007) 1.38
Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay. BMC Cancer (2010) 1.38
Pathways to cancer therapy. Nat Rev Drug Discov (2008) 1.16
Group additive regression models for genomic data analysis. Biostatistics (2007) 1.13
The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet (2004) 9.37
EBSeq: an empirical Bayes hierarchical model for inference in RNA-seq experiments. Bioinformatics (2013) 4.79
A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibility. Genome Res (2008) 4.33
Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One (2008) 4.24
Genetic networks of liver metabolism revealed by integration of metabolic and transcriptional profiling. PLoS Genet (2008) 2.63
Resource utilization for ovarian cancer patients at the end of life: how much is too much? Gynecol Oncol (2005) 2.26
Top-down quantitative proteomics identified phosphorylation of cardiac troponin I as a candidate biomarker for chronic heart failure. J Proteome Res (2011) 2.17
A microRNA expression signature for cervical cancer prognosis. Cancer Res (2010) 2.14
Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol (2004) 2.08
Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys (2009) 2.05
Combined expression trait correlations and expression quantitative trait locus mapping. PLoS Genet (2006) 1.93
A statistical framework for Illumina DNA methylation arrays. Bioinformatics (2010) 1.92
Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin Oncol (2007) 1.87
Obesity and genetics regulate microRNAs in islets, liver, and adipose of diabetic mice. Mamm Genome (2009) 1.87
Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A (2003) 1.83
A PtdIns4,5P2-regulated nuclear poly(A) polymerase controls expression of select mRNAs. Nature (2008) 1.79
Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol (2002) 1.72
Cervical carcinoma in the elderly: an analysis of patterns of care and outcome. Cancer (2005) 1.68
Pattern discovery and cancer gene identification in integrated cancer genomic data. Proc Natl Acad Sci U S A (2013) 1.60
Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA (2009) 1.60
Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors. Gynecol Oncol (2009) 1.59
Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet (2004) 1.57
Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol (2010) 1.55
A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol (2007) 1.53
Low serum magnesium is associated with decreased graft survival in patients with chronic cyclosporin nephrotoxicity. Nephrol Dial Transplant (2005) 1.48
Statistical methods for gene set co-expression analysis. Bioinformatics (2009) 1.47
A unified approach for simultaneous gene clustering and differential expression identification. Biometrics (2006) 1.42
Effect of physician gender and specialty on utilization of hysterectomy in New York, 2001-2005. Am J Obstet Gynecol (2008) 1.40
Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy. Cancer (2007) 1.38
Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clin Cancer Res (2003) 1.36
Variable selection for multiply-imputed data with application to dioxin exposure study. Stat Med (2013) 1.28
Liver gene expression analysis reveals endoplasmic reticulum stress and metabolic dysfunction in SCD1-deficient mice fed a very low-fat diet. Physiol Genomics (2008) 1.26
ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. J Clin Oncol (2009) 1.25
Gene expression profiling in INS-1 cells overexpressing thioredoxin-interacting protein. Biochem Biophys Res Commun (2005) 1.23
Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer (2005) 1.20
Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. Cancer Res (2007) 1.17
Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol (2004) 1.15
The IRP1-HIF-2α axis coordinates iron and oxygen sensing with erythropoiesis and iron absorption. Cell Metab (2013) 1.14
Cervix carcinoma, concurrent chemoradiotherapy, and salvage of isolated paraaortic lymph node recurrence. Int J Radiat Oncol Biol Phys (2005) 1.11
Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines. Clin Gastroenterol Hepatol (2009) 1.11
Disease progression and outcomes in chronic kidney disease and renal transplantation. Kidney Int (2003) 1.10
Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer. Clin Cancer Res (2012) 1.09
Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol (2002) 1.08
Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer (2006) 1.07
Variable selection and estimation in generalized linear models with the seamless L0 penalty. Can J Stat (2012) 1.06
Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer. Gynecol Oncol (2006) 1.05
The osteoblast to osteocyte transition: epigenetic changes and response to the vitamin D3 hormone. Mol Endocrinol (2014) 1.02
Cervical tissue collection methods for RNA preservation: comparison of snap-frozen, ethanol-fixed, and RNAlater-fixation. Diagn Mol Pathol (2006) 1.02
CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer. Cancer Res (2007) 1.01
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol (2010) 1.01
An empirical Bayesian approach for identifying differential coexpression in high-throughput experiments. Biometrics (2011) 1.00
DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. Mod Pathol (2006) 0.99
The influence of macrophage depletion on ligament healing. Connect Tissue Res (2010) 0.99
Integrative analysis of a cross-loci regulation network identifies App as a gene regulating insulin secretion from pancreatic islets. PLoS Genet (2012) 0.98
Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning. Cancer Res (2008) 0.98
Discovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis. BMC Genomics (2013) 0.98
HLA-Cw group 1 ligands for KIR increase susceptibility to invasive cervical cancer. Immunogenetics (2010) 0.97
Cervical sarcomas: an analysis of incidence and outcome. Gynecol Oncol (2005) 0.96
Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecol Oncol (2002) 0.96
The significance of pneumatosis intestinalis or bowel perforation in patients with gynecologic malignancies. Gynecol Oncol (2002) 0.96
R/EBcoexpress: an empirical Bayesian framework for discovering differential co-expression. Bioinformatics (2012) 0.95
Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol (2008) 0.95
Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma. Gynecol Oncol (2005) 0.94
Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res (2007) 0.94
IGSF4 promoter methylation and expression silencing in human cervical cancer. Gynecol Oncol (2005) 0.94
Evaluation of candidate methylation markers to detect cervical neoplasia. Gynecol Oncol (2007) 0.94
Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res (2004) 0.94
Quantitative trait loci associated with susceptibility to bladder and kidney infections induced by Escherichia coli in female C3H/HeJ mice. J Infect Dis (2009) 0.94
Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol (2008) 0.93
A dominantly acting murine allele of Mcm4 causes chromosomal abnormalities and promotes tumorigenesis. PLoS Genet (2012) 0.92
External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial cancer. Gynecol Oncol (2007) 0.91
A model-based analysis to infer the functional content of a gene list. Stat Appl Genet Mol Biol (2012) 0.91
Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker. Cancer (2002) 0.90
Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol (2006) 0.90
Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol (2002) 0.90
Transcriptional and functional adaptations of human endothelial cells to physiological chronic low oxygen. Biol Reprod (2013) 0.89
Metabolic changes in skin caused by Scd1 deficiency: a focus on retinol metabolism. PLoS One (2011) 0.89
The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer (2010) 0.89
Qualitative Evaluation of Medical Information Processing Needs of 60 Women Choosing Ovarian Cancer Surveillance or Prophylactic Oophorectomy. J Genet Couns (2002) 0.88
TP53, MDM2, NQO1, and susceptibility to cervical cancer. Cancer Epidemiol Biomarkers Prev (2010) 0.88
Patient clinical factors influencing use of hysterectomy in New York, 2001-2005. Am J Obstet Gynecol (2008) 0.88
Differential display identifies overexpression of the USP36 gene, encoding a deubiquitinating enzyme, in ovarian cancer. Int J Med Sci (2008) 0.88
Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial carcinoma. Int J Radiat Oncol Biol Phys (2006) 0.87
Exenatide blocks JAK1-STAT1 in pancreatic beta cells. Metabolism (2007) 0.87
Synchronous ovarian metastases at the time of laparotomy for colon cancer. Gynecol Oncol (2004) 0.87
CD83 polymorphisms and cervical cancer risk. Gynecol Oncol (2009) 0.86
Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive endometrial carcinoma lacking MLH1 promoter methylation. Clin Cancer Res (2004) 0.86
Cervical dysplasia in adolescents. Obstet Gynecol (2005) 0.85
Platelet-rich plasma for the treatment of chronic plantar fasciopathy in adults: a case series. Foot Ankle Spec (2013) 0.85
Colposcopic accuracy of obstetrics and gynecology residents. Gynecol Oncol (2006) 0.85
A statistical framework for expression quantitative trait loci mapping. Genetics (2007) 0.85
"Surgical Apgar Score" predicts postoperative complications after cytoreduction for advanced ovarian cancer. Gynecol Oncol (2009) 0.85
Group variable selection via convex log-exp-sum penalty with application to a breast cancer survivor study. Biometrics (2014) 0.85
Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake. Cancer (2009) 0.84
College adjustment in University of Michigan students with Crohn's and colitis. Inflamm Bowel Dis (2008) 0.84
Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol (2013) 0.84
An efficient method for identifying statistical interactors in gene association networks. Biostatistics (2009) 0.84
MLH3 mutation in endometrial cancer. Cancer Res (2006) 0.84
The influence of interleukin-4 on ligament healing. Wound Repair Regen (2011) 0.83
Long-term assessment of bladder and bowel dysfunction after radical hysterectomy. Gynecol Oncol (2009) 0.83